BillionToOne targets over $2 billion valuation in US IPO

Group 1 - The core focus of the article is that molecular diagnostics firm BillionToOne is targeting a valuation of up to $2.42 billion in its upcoming U.S. initial public offering [1] Group 2 - BillionToOne is a company operating in the molecular diagnostics industry, which is a sector that focuses on the development and commercialization of diagnostic tests based on molecular biology techniques [1]